#$MU Citi cuts Micron price target, but the rationale does not hold

#$MU Citi cuts Micron price target, but the rationale does not hold
On August 7, Citi cut Micron's price target from $1,400 to $1,150, while maintaining a Buy rating. Ten days later, UBS published a report written after accompanying Micron's management on a roadshow, with a $1,625 price target and the same Buy rating. The two targets differ by $475. But when you look at the earnings forecasts from both firms, they are nearly identical. UBS estimates Micron will earn $148 per share in 2028, while Citi estimates $148.60, a difference of less than 1%. The two firms do not disagree on how much Micron can earn. The disagreement is over how many times those profits are worth.

01 What exactly did Citi cut?
Citi's report was published on August 7 by analysts Atif Malik, James Bowlin, and Kelsey Chia, and runs 14 pages. Its pricing benchmark was the August 6 closing price of $881.47. The new $1,150 price target corresponds to 8 times expected 2027 calendar-year EPS. The previous target was based on 10 times. The earnings forecast section barely changed. The 2027 fiscal-year forecast was lowered by 1%, and the 2028 fiscal-year forecast by 2%. In other words, Citi's view of how much Micron can earn has barely changed; what changed is how much it thinks the market is willing to pay for those profits. The price target fell 17.9%, with only 1% to 2% of the reduction coming from earnings adjustments; all the rest came from multiple compression. Supporting this decision is a DRAM price trajectory.
Citi expects the increase to narrow each quarter: still over 20% in the August quarter, below 10% in the November quarter, just 2% next February, zero in May, and down 5% in the second half of 2027.
NAND is expected to follow a similar path. The corresponding gross margin retreats from around 85% to around 75%. Section 4.4 of the report also contains a detail that was not included in the summary and was not mentioned in any articles citing it: Approximately 40% of Micron's DRAM output is covered by long-term contracts, the lowest among the four major memory manufacturers. The remaining approximately 60% is exposed to spot prices, giving Micron greater exposure than Samsung and SK hynix.

02 UBS heard a different story from management
On August 17, UBS published “Walking Alongside Management.” The report was written after accompanying Micron's management on a round of investor roadshows. It maintained a Buy rating and set a $1,625 price target, 41% above Citi's. The two firms diverge in three areas.
1. Their views on the price trajectory are completely opposite. Citi believes DRAM price increases will decline each quarter, reach zero by the middle of next year, and turn negative in the second half. UBS recorded management's exact words: Supply and demand in calendar 2027 will be tighter than in 2026. Micron currently meets less than half of data-center customer demand, while average HBM selling prices are still rising. UBS also listed capacity milestones: Most of the new capacity in 2027 will come from expansions at two older fabs, and the volume will be limited. Truly large-scale production will have to wait until 2028. Supply pressure has been pushed back by a year. Citi says “the peak is near,” while management says “we haven't reached the peak yet.” Within ten days, the pricing trajectory had been drawn in opposite directions.
2. Their descriptions of long-term contract coverage also differ. Citi says approximately 40% of Micron's output is covered by long-term contracts, the lowest among the four companies. UBS was the first to break down the structure of Micron's strategic customer agreements: The goal is to bring more than 50% of revenue under contractual protection, with approximately 10% on a “take-or-pay” basis (customers can decline delivery but must still pay; prices are not locked), and another approximately 40% carrying fixed prices or price ranges. Citi uses an output-based measure, while UBS uses a revenue-based measure, so the two figures cannot be directly compared. But the direction of their statements is opposite: Citi says “the least is locked in,” while UBS says “more than 50% of revenue has three layers of protection.”
3. Their valuation bases differ by an entire year. Citi uses 8 times 2027 calendar-year earnings. UBS uses 11 times 2028 calendar-year EPS of $148. Citi's own forecast for Micron's 2028 fiscal-year EPS is $148.60. Multiplying Citi's earnings forecast by UBS's multiple produces $1,635, just 0.6% above UBS's $1,625.
The two firms differ by $475, their earnings forecasts are nearly identical, and the entire disagreement lies in “which year to look at” and “what multiple to assign.”

03 Both firms have conflicts of interest
Citi's self-disclosed conflict level is medium to high, including investment banking compensation and significant financial interests.
UBS's situation deserves more attention: It holds a short position of more than 0.5% in Micron while also serving as a market maker in Micron stock, yet it gave the company a Buy rating and the highest price target on Wall Street. One firm has investment banking business with the company yet cut its price target. The other holds a short position yet set the highest price target. Neither side's interests are clean.

04 Citi's cut does not hold up this time
Earnings forecasts were changed by only 1% to 2%, yet the price target fell 17.9%. What was cut was not Micron's earnings power, but the valuation multiple Citi believes the market should assign. That is a subjective judgment, not a business discovery.
More importantly, the price assumption supporting that judgment—the DRAM increase narrowing each quarter and reaching zero by the middle of next year—was directly rejected by Micron's management ten days after the report was issued. Management said 2027 will be tighter than 2026, new capacity will not arrive until 2028, and the company currently cannot even meet half of data-center demand. Citi also has an internal contradiction. It maintains a Buy rating while keeping its earnings forecasts 13% to 15% below consensus. Its reason for being bullish on Micron is that the stock is cheap, but its own model does not support the claim that “the company can earn more.” $1,150 looks more like a conservative floor. But UBS's $1,625 cannot be accepted wholesale either. That target was set on May 26 and has not been updated for three months. A price target that goes unchanged for three months is closer to a statement of conviction. Moreover, the institution that issued it is itself holding a short position in Micron.
SUMMARY Only one conclusion stands
Citi's cut this time was to the valuation multiple, not the fundamentals. Reducing a position alongside Citi means following Citi's valuation preference rather than following changes in Micron's operations. As for whether Micron should continue to be held, all three reports sidestep the same key question: Does HBM output count toward that 40% long-term contract coverage? This gap determines how much pricing exposure Micron's conventional DRAM actually has. None of the three reports provides an answer.

What to watch next
① If Micron's next earnings report discloses long-term contract coverage significantly above 40%, the claim that it is “the least locked in among the four” will no longer hold.
② If DRAM prices really follow the line Citi drew—quarterly growth falling below 10% in the November quarter and leaving just 2% next February—then management was wrong and Citi was right.
③ If UBS's next update still leaves the target at $1,625, no change for three months reflects conviction; no change for six months means it has not been tracking the company. $MU ‌